FI115400B - Menetelmä oligoribonukleotidi- ja ribotsyymianalogien valmistamiseksi, joissa on terminaaliset 3 '-3'- tai 5'-5'-sidokset - Google Patents

Menetelmä oligoribonukleotidi- ja ribotsyymianalogien valmistamiseksi, joissa on terminaaliset 3 '-3'- tai 5'-5'-sidokset Download PDF

Info

Publication number
FI115400B
FI115400B FI934154A FI934154A FI115400B FI 115400 B FI115400 B FI 115400B FI 934154 A FI934154 A FI 934154A FI 934154 A FI934154 A FI 934154A FI 115400 B FI115400 B FI 115400B
Authority
FI
Finland
Prior art keywords
formula
alkyl
residue
groups
oligoribonucleotides
Prior art date
Application number
FI934154A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI934154A (fi
FI934154A0 (fi
Inventor
Heinz Hartmut Seliger
Flavio Ramalho Ortigao
Hannelore Roesch
Rudi Roesch
Bernd Krist
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6468696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI115400(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of FI934154A0 publication Critical patent/FI934154A0/fi
Publication of FI934154A publication Critical patent/FI934154A/fi
Application granted granted Critical
Publication of FI115400B publication Critical patent/FI115400B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Shaping Of Tube Ends By Bending Or Straightening (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI934154A 1992-09-24 1993-09-22 Menetelmä oligoribonukleotidi- ja ribotsyymianalogien valmistamiseksi, joissa on terminaaliset 3 '-3'- tai 5'-5'-sidokset FI115400B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4231949 1992-09-24
DE4231949 1992-09-24

Publications (3)

Publication Number Publication Date
FI934154A0 FI934154A0 (fi) 1993-09-22
FI934154A FI934154A (fi) 1994-03-25
FI115400B true FI115400B (fi) 2005-04-29

Family

ID=6468696

Family Applications (1)

Application Number Title Priority Date Filing Date
FI934154A FI115400B (fi) 1992-09-24 1993-09-22 Menetelmä oligoribonukleotidi- ja ribotsyymianalogien valmistamiseksi, joissa on terminaaliset 3 '-3'- tai 5'-5'-sidokset

Country Status (14)

Country Link
US (1) US6420546B1 (el)
EP (1) EP0593901B2 (el)
JP (1) JP3653102B2 (el)
AT (1) ATE151773T1 (el)
AU (1) AU665113B2 (el)
CA (1) CA2106819C (el)
DE (1) DE59306170D1 (el)
DK (1) DK0593901T3 (el)
ES (1) ES2103408T3 (el)
FI (1) FI115400B (el)
GR (1) GR3023858T3 (el)
HU (1) HU219638B (el)
NO (1) NO307656B1 (el)
NZ (1) NZ248739A (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
PT808898E (pt) * 1996-05-24 2004-10-29 Aventis Pharma Gmbh Reagente e metodo para inibicao da expressao de n-ras
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
CA2326823A1 (en) * 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
EP2322648A1 (en) 2000-09-26 2011-05-18 Duke University RNA aptamers and methods for identifying the same
SG157961A1 (en) 2001-05-25 2010-01-29 Univ Duke Modulators of pharmacological agents
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
ES2494940T3 (es) 2004-04-22 2014-09-16 Regado Biosciences, Inc. Moduladores de factores de coagulación mejorados
US7923206B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
EP1820804A1 (en) * 2006-02-20 2007-08-22 Humboldt-Universität zu Berlin Lipidated oligonucleotides
WO2008036841A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
US7845686B2 (en) * 2007-12-17 2010-12-07 S & B Technical Products, Inc. Restrained pipe joining system for plastic pipe
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2781523A1 (en) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Lipophilic oligonucleotide analogs
CN110023321A (zh) 2016-08-17 2019-07-16 索尔斯蒂斯生物有限公司 多核苷酸构建体
EP3645546A4 (en) 2017-06-30 2021-12-01 Solstice Biologics, Ltd. CHIRAL PHOSPHORAMIDITIS AUXILIARIES AND THEIR METHODS OF USE
US11104941B2 (en) * 2018-09-28 2021-08-31 Bioo Scientific Corporation 5′ adapter comprising an internal 5′-5′ linkage

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3916871A1 (de) 1989-05-24 1990-11-29 Boehringer Mannheim Gmbh Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
ES2099718T3 (es) * 1990-07-02 1997-06-01 Hoechst Ag Analogos de oligonucleotidos con uniones internucleotidicas de 3'-3' o 5'-5' terminales.
US5672697A (en) * 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
KR930016437A (ko) * 1992-01-22 1993-08-26 귀틀라인, 슈미트 올리고뉴클레오티드 유사체, 이의 제조방법 및 용도

Also Published As

Publication number Publication date
NO933397D0 (no) 1993-09-23
CA2106819A1 (en) 1994-03-25
ES2103408T3 (es) 1997-09-16
EP0593901B1 (de) 1997-04-16
AU665113B2 (en) 1995-12-14
FI934154A (fi) 1994-03-25
FI934154A0 (fi) 1993-09-22
NO933397L (no) 1994-03-25
JP3653102B2 (ja) 2005-05-25
NZ248739A (en) 1995-08-28
AU4755193A (en) 1994-03-31
HU219638B (hu) 2001-06-28
HU9302697D0 (en) 1993-12-28
US6420546B1 (en) 2002-07-16
EP0593901A2 (de) 1994-04-27
EP0593901A3 (en) 1994-09-28
DE59306170D1 (de) 1997-05-22
GR3023858T3 (en) 1997-09-30
HUT66458A (en) 1994-11-28
ATE151773T1 (de) 1997-05-15
DK0593901T3 (da) 1997-10-27
CA2106819C (en) 2007-04-17
EP0593901B2 (de) 2008-04-09
JPH06189753A (ja) 1994-07-12
NO307656B1 (no) 2000-05-08

Similar Documents

Publication Publication Date Title
FI115400B (fi) Menetelmä oligoribonukleotidi- ja ribotsyymianalogien valmistamiseksi, joissa on terminaaliset 3 '-3'- tai 5'-5'-sidokset
CA2045891C (en) Oligonucleotide analogs with terminal 3'-3' or 5'-5' internucleotide linkages
JP6233903B2 (ja) 架橋型ヌクレオシドおよびヌクレオチド
US5955599A (en) Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages
JP4731324B2 (ja) Ｎ−ｏ結合性架橋構造型新規人工核酸
ES2244957T3 (es) Oligonucleotidos modificados, su preparacion, asi como su empleo.
EP2217612B1 (en) Preparation of ribonucleotide oligomer
JP2013520438A (ja) 逆方向合成ｒｎａのためのホスホルアミダイト
EP1100809A1 (en) Rna targeted 2'-modified oligonucleotides that are conformationally preorganized
WO2020072991A1 (en) Modified oligomeric compounds and uses thereof
Lauritsen et al. Oligodeoxynucleotides containing amide-linked LNA-type dinucleotides: synthesis and high-affinity nucleic acid hybridization
Marsh et al. The synthesis and properties of oligoribonucleotide–spermine conjugates
Decuypere et al. Increased Affinity of 2′‐O‐(2‐Methoxyethyl)‐Modified Oligonucleotides to RNA through Conjugation of Spermine at Cytidines
Sandbrink et al. Investigation of potential RNA bulge stabilizing elements
Suydam et al. Nucleotide analog interference mapping
RU2088588C1 (ru) Олигонуклеотиды и способ их получения
Reddy et al. Elimination of transamination side product by the use of dCAc methylphosphonamidite in the synthesis of oligonucleoside methylphosphonates
WO2024049312A2 (en) A method for the synthesis and purification of a nucleotide and/or a nucleoside, a modified nucleotide and/or a nucleoside, a dna molecule containing a single- or double-stranded oligonucleotide chain, an oligonucleotide library, use of the oligonucleotide library
Zatsepin et al. Synthesis of (2′ S)‐and (2′ R)‐2′‐Deoxy‐2′‐[(2‐methoxyethoxy) amino] Pyrimidine Nucleosides and Oligonucleotides
KR20230074205A (ko) 핵산 올리고머의 제조 방법
Wu Synthesis of 5'-C-and 2'-O-substituted oligoribonucleotide analogues and evaluation of their pairing properties
Blackburn et al. Nucleic acids
JPWO2005085270A1 (ja) ピリジン環５位にピロリル基を導入した核酸誘導体
WO1996018640A9 (el)
PL219355B1 (pl) Modyfikowany deoksyrybozym 10-23 o ustabilizowanej odporności na hydrolizę oraz podwyższonej aktywności katalitycznej i sposób jego wytwarzania

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 115400

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH

Free format text: SANOFI-AVENTIS DEUTSCHLAND GMBH